Table S3.
miR-200a treatment | miR-200b treatment | Glycan type | ||||
Glycogene | Fold change | P value | Glycogene | Fold change | P value | |
Shared predicted targets | ||||||
MGAT4A | 1.06 | 0.74 | MGAT4A | 1.17 | 0.31 | N-linked |
C1GALT1 | −1.19 | 0.050 | C1GALT1 | −1.10 | 0.40 | O-linked |
GALNT14 | −1.49 | 0.011 | GALNT14 | −1.94 | 0.0059 | |
*B3GLCT | −1.06 | 0.69 | *B3GLCT | −1.61 | 0.0042 | NC O-linked |
*ST3GAL5 | −1.61 | 0.0064 | *ST3GAL5 | −2.13 | 2.1E-0.4 | Glycolipid |
ST6GALNAC3 | 1.62 | 0.20 | ST6GALNAC3 | 1.11 | 0.76 | |
B3GNT2 | 1.07 | 0.66 | B3GNT2 | 1.22 | 0.15 | Other/terminal |
miR-200b/-200c/-429 predicted targets | ||||||
*MGAT2 | −1.08 | 0.72 | *MGAT2 | 1.01 | 0.98 | N-linked |
MGAT3 | −1.86 | 0.12 | MGAT3 | 1.30 | 0.15 | |
MGAT4C | 1.93 | 0.20 | MGAT4C | −1.00 | 1.00 | |
GALNT2 | −1.09 | 0.52 | GALNT2 | −1.40 | 0.022 | O-linked |
GALNT3 | 1.03 | 0.71 | GALNT3 | 2.30 | 4.5E-0.4 | |
GALNT10 | −1.14 | 0.11 | GALNT10 | −1.68 | 0.0012 | |
GALNT11 | −1.11 | 0.29 | GALNT11 | −1.26 | 0.011 | |
GALNT12 | −1.40 | 0.0074 | GALNT12 | −1.52 | 0.0063 | |
GCNT4 | −1.18 | 0.16 | GCNT4 | −1.05 | 0.79 | |
LFNG | −1.49 | 0.21 | LFNG | −2.14 | 0.074 | NC O-linked |
MGEA5 | −1.06 | 0.58 | MGEA5 | 1.02 | 0.71 | |
CHSY3 | 1.15 | 0.36 | CHSY3 | −1.04 | 0.68 | GAGs |
HS3ST1 | 1.99 | 0.044 | HS3ST1 | 3.28 | 0.014 | |
HS3ST3A1 | −1.11 | 0.74 | HS3ST3A1 | −1.24 | 0.39 | |
B3GALNT1 | −1.11 | 0.56 | B3GALNT1 | −1.16 | 0.46 | Glycolipid |
*ST6GALNAC5 | 2.23 | 0.033 | *ST6GALNAC5 | 4.79 | 0.010 | |
B3GNT1 | −1.04 | 0.80 | B3GNT1 | −1.47 | 0.039 | Other/terminal |
ST3GAL2 | −1.18 | 0.20 | ST3GAL2 | −1.59 | 0.0012 | |
ST8SIA4 | −1.23 | 0.013 | ST8SIA4 | −1.15 | 0.22 | |
miR-200a/141 predicted targets | ||||||
GALNT4 | −1.16 | 0.20 | GALNT4 | −1.17 | 0.077 | O-linked |
POFUT1 | −1.00 | 0.98 | POFUT1 | −1.01 | 0.90 | NC O-linked |
B3GALT6 | 1.05 | 0.83 | B3GALT6 | 1.00 | 0.99 | GAGs |
B3GNT4 | 1.29 | 0.075 | B3GNT4 | 2.24 | 6.4E-04 | Glycolipid |
B3GNT5 | 1.25 | 0.11 | B3GNT5 | 1.70 | 0.0026 | |
*ST3GAL6 | −1.18 | 0.30 | *ST3GAL6 | 1.01 | 0.91 | |
*ST3GAL3 | −1.42 | 0.051 | *ST3GAL3 | −1.43 | 0.035 | Other/terminal |
MDA-MB-231 cells were treated with miR-200a, miR-200b, or scramble mimics (50 nM) for 7 d. qRT-PCR was performed using RT2 Profiler PCR Array Human Glycosylation (Qiagen) or custom primers for genes not represented on the array (Dataset S1). Fold change (miR-treated/scramble) was calculated by taking the average relative expression of miR-treated samples (n = 4 independent experiments, normalized to GAPDH) over the average relative expression of the scramble-treated cells (n = 4 independent experiments, normalized to GAPDH). Where the fold change was less than 1, the negative inverse is shown. P values for treated vs. scramble were calculated using Student's t-test. Statistically significant (P ≤ 0.05) down-regulation is in bold; up-regulation is underlined. GAGs, glycosaminoglycans; NC O-linked, noncanonical O-linked; See Table S1 for glycan type distribution.
Genes for which luciferase data were obtained (Fig. 1).